Akums Drugs and Pharmaceuticals Ltd
NSE:AKUMS
Akums Drugs and Pharmaceuticals Ltd
Akums Drugs and Pharmaceuticals Ltd., an unsung hero within India's healthcare sector, crafts its narrative through a robust commitment to pharmaceutical manufacturing. Founded in 2004, this company quietly emerged as a formidable provider of contract drug manufacturing solutions. Instead of marketing its own branded products, Akums positions itself as the silent partner behind many well-known pharmaceutical names, providing vital production services. By offering end-to-end manufacturing, from raw material sourcing to finished product packaging, Akums ensures that pharmaceutical companies can concentrate on their strengths: marketing and distribution.
The company thrives on its vast portfolio, which encompasses the manufacture of nearly every form of a pharmaceutical product—be it tablets, capsules, injectables, or topical treatments. Akums drives revenue through partnerships, where it functions as the backbone of production lines for its clients. Utilizing cutting-edge technology and stringent global standards, Akums not only addresses the varied needs of the pharmaceutical industry but also adapts to the ever-evolving demands of healthcare worldwide. This strategic focus on high-quality contract manufacturing fuels its financial success, allowing it to expand facilities and scale operations, while maintaining a discreet presence that underscores its core philosophy: to innovate in service rather than spotlight.
Akums Drugs and Pharmaceuticals Ltd., an unsung hero within India's healthcare sector, crafts its narrative through a robust commitment to pharmaceutical manufacturing. Founded in 2004, this company quietly emerged as a formidable provider of contract drug manufacturing solutions. Instead of marketing its own branded products, Akums positions itself as the silent partner behind many well-known pharmaceutical names, providing vital production services. By offering end-to-end manufacturing, from raw material sourcing to finished product packaging, Akums ensures that pharmaceutical companies can concentrate on their strengths: marketing and distribution.
The company thrives on its vast portfolio, which encompasses the manufacture of nearly every form of a pharmaceutical product—be it tablets, capsules, injectables, or topical treatments. Akums drives revenue through partnerships, where it functions as the backbone of production lines for its clients. Utilizing cutting-edge technology and stringent global standards, Akums not only addresses the varied needs of the pharmaceutical industry but also adapts to the ever-evolving demands of healthcare worldwide. This strategic focus on high-quality contract manufacturing fuels its financial success, allowing it to expand facilities and scale operations, while maintaining a discreet presence that underscores its core philosophy: to innovate in service rather than spotlight.
Strong Revenue Growth: Akums reported Q3 FY '26 operating revenue of INR 1,160 crores, up 14.8% year-on-year and 14% quarter-on-quarter, driven by robust performance in the CDMO and international branded formulation businesses.
Margin Expansion: EBITDA margin improved to 12.7%, up 65 bps YoY and 338 bps QoQ, with segmental gains from operating leverage and cost control.
CDMO Momentum: CDMO revenue rose 16.3% YoY, with broad-based double-digit volume growth and stable or slightly improved gross margins.
API Losses Narrow: API segment continued to see pricing pressure but losses narrowed due to rationalization and cost optimization.
International & Zambia Projects: Progress continued on European and Zambia projects; EU Plant 2 received GMP approval, and Zambia contract supply of $25 million expected in both CY '26 and CY '27.
Healthy Cash Position: Strong cash surplus of INR 1,573 crores with cash flow from operations at INR 1,109.5 crores.
Guidance: Management expects volume and margin momentum to sustain in Q4, with growth drivers in place for the next year.
